-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 26, the latest analysis of the EAST-AFNET 4 study published in the leading cardiovascular journal JACC confirmed that early rhythm control can reduce the risk of stroke in patients with atrial fibrillation (hereinafter referred to as "atrial fibrillation", AF.
Pay attention to atrial fibrillation, don't let stroke take advantage of it
Atrial fibrillation is when the heart beats out of its normal rhyth.
Early rhythm control significantly improves quality of life in patients with atrial fibrillation
At present, rhythm control in patients with atrial fibrillation can be achieved clinically through drug therapy, radiofrequency ablation, and electrical cardioversion, which significantly reduces the incidence of serious complication.
Professor Dong Yugang from the First Affiliated Hospital of Sun Yat-Sen University said: "If it is a new-onset atrial fibrillation patient with underlying heart disease, we usually give priority to drug treatment, using antiarrhythmic drugs to control atrial fibrillation and enable the patient to recove.
The results of the prespecified analysis of the EAST-AFNET 4 study recently published by the authoritative journal JACC in the cardiovascular field[ii] suggest that early rhythm control can reduce the three different manifestations of first-diagnosed atrial fibrillation, paroxysmal atrial fibrillation and persistent atrial fibrillation risk of cardiovascular death, stroke, hospitalization for heart failure and acute coronary syndrome in patients with atrial fibrillatio.
Professor Dong Yugang pointed out: "Clinically, when a patient has symptoms or begins to feel uncomfortable, we all recommend that the patient receive treatment as soon as possibl.
Improve access to new medicines and benefit more patient groups
Since the new antiarrhythmic drug dronedarone hydrochloride tablets was launched in the United States and Europe in 2009, more than 15 million patients with atrial fibrillation have used dronedarone hydrochloride tablets worldwid.
Dronedarone Hydrochloride Tablets are structurally optimized on the basis of amiodaron.
Professor Dong Yugang pointed out, "At present, there are not many drugs to choose from in Chin.
The successful launch of dronedarone hydrochloride tablets in China provides a new long-acting and safe drug choice for early rhythm control in patients with atrial fibrillatio.
About the disease status of atrial fibrillation in China
According to the latest epidemiological data, there are more than 20 million patients with atrial fibrillation in Chin.